Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D E Shapiro

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Journal of Psychosomatic Research|August 1, 1997
Stage II breast cancer: differences between four coping patterns in side effects during adjuvant chemotherapyD E Shapiro, S R Boggs, J R Rodrigue, et al.
The Journal of Pediatrics|June 4, 1999
The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type-1 (Pediatric AIDS Clinical Trials Group Protocol 076)G D McSherry, D E Shapiro, R W Coombs, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 1, 1994
A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndromeD R Strayer, W A Carter, I Brodsky, et al.
The Journal of Infectious Diseases|March 14, 1998
Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076P S Eastman, D E Shapiro, R W Coombs, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|May 4, 1999
Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudineI C Hanson, T A Antonelli, R S Sperling, et al.
Radiology|August 3, 1999
Ovarian cancer: comparison of observer performance for four methods of interpreting CT scansP J Fultz, C V Jacobs, W J Hall, et al.
The Journal of Infectious Diseases|April 1, 1997
Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1L M Frenkel, M K Cowles, D E Shapiro, et al.
Journal of Clinical Microbiology|February 12, 1998
Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisonsD Brambilla, S Leung, J Lew, et al.
AIDS (London, England)|November 24, 1999
The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance ProgramD Brambilla, P S Reichelderfer, J W Bremer, et al.
The New England Journal of Medicine|November 28, 1996
Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study GroupR S Sperling, D E Shapiro, R W Coombs, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Journal of Psychosomatic Research|August 1, 1997
Stage II breast cancer: differences between four coping patterns in side effects during adjuvant chemotherapyD E Shapiro, S R Boggs, J R Rodrigue, et al.
The Journal of Pediatrics|June 4, 1999
The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type-1 (Pediatric AIDS Clinical Trials Group Protocol 076)G D McSherry, D E Shapiro, R W Coombs, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 1, 1994
A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndromeD R Strayer, W A Carter, I Brodsky, et al.
The Journal of Infectious Diseases|March 14, 1998
Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076P S Eastman, D E Shapiro, R W Coombs, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|May 4, 1999
Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudineI C Hanson, T A Antonelli, R S Sperling, et al.
Radiology|August 3, 1999
Ovarian cancer: comparison of observer performance for four methods of interpreting CT scansP J Fultz, C V Jacobs, W J Hall, et al.
The Journal of Infectious Diseases|April 1, 1997
Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1L M Frenkel, M K Cowles, D E Shapiro, et al.
Journal of Clinical Microbiology|February 12, 1998
Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisonsD Brambilla, S Leung, J Lew, et al.
AIDS (London, England)|November 24, 1999
The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance ProgramD Brambilla, P S Reichelderfer, J W Bremer, et al.
The New England Journal of Medicine|November 28, 1996
Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study GroupR S Sperling, D E Shapiro, R W Coombs, et al.
Pageof 4